|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan
Z, Wan X, Liu G, Wu D, Shi L, et al: Prognostic nomogram for
intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin
Oncol. 31:1188–1195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haga H and Patel T: Molecular diagnosis of
intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci.
22:114–123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bridgewater J, Galle PR, Khan SA, Llovet
JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the
diagnosis and management of intrahepatic cholangiocarcinoma. J
Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okumura S, Kaido T, Hamaguchi Y, Kobayashi
A, Shirai H, Fujimoto Y, Iida T, Yagi S, Taura K, Hatano E, et al:
Impact of skeletal muscle mass, muscle quality, and visceral
adiposity on outcomes following resection of intrahepatic
cholangiocarcinoma. Ann Surg Oncol. 24:1037–1045. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma NF, Hu L, Fung JM, Xie D, Zheng BJ,
Chen L, Tang DJ, Fu L, Wu Z, Chen M, et al: Isolation and
characterization of a novel oncogene, amplified in liver cancer 1,
within a commonly amplified region at 1q21 in hepatocellular
carcinoma. Hepatology. 47:503–510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng W, Su Y and Xu F: CHD1L: A novel
oncogene. Mol Cancer. 12:1702013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ,
Huang J and Guan XY: Clinical significance of CHD1L in
hepatocellular carcinoma and therapeutic potentials of
virus-mediated CHD1L depletion. Gut. 60:534–543. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu J, Zong Y, Fei X, Chen X, Huang O, He
J, Chen W, Li Y, Shen K and Zhu L: Presence of CHD1L
over-expression is associated with aggressive tumor biology and is
a novel prognostic biomarker for patient survival in human breast
cancer. PLoS One. 9:e986732014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su Z, Zhao J, Xian G, Geng W, Rong Z, Wu Y
and Qin C: CHD1L is a novel independent prognostic factor for
gastric cancer. Clin Transl Oncol. 16:702–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su FR, Ding JH, Bo L and Liu XG:
Chromodomain helicase/ATPase DNA binding protein 1-like protein
expression predicts poor prognosis in nasopharyngeal carcinoma. Exp
Ther Med. 8:1745–1750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He WP, Zhou J, Cai MY, Xiao XS, Liao YJ,
Kung HF, Guan XY, Xie D and Yang GF: CHD1L protein is overexpressed
in human ovarian carcinomas and is a novel predictive biomarker for
patients survival. BMC Cancer. 12:4372012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Farges O, Fuks D, Le Treut YP, Azoulay D,
Laurent A, Bachellier P, Nuzzo G, Belghiti J, Pruvot FR and
Regimbeau JM: AJCC 7th edition of TNM staging accurately
discriminates outcomes of patients with resectable intrahepatic
cholangiocarcinoma. Cancer. 117:2170–2177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Renshaw S: Immunohistochemistry and
immunocytochemistry: Essential methods. John Wiley Sons.
6:2482017.
|
|
16
|
Li J, Guan HY, Gong LY, Song LB, Zhang N,
Wu J, Yuan J, Zheng YJ, Huang ZS and Li M: Clinical significance of
sphingosine kinase-1 expression in human astrocytomas progression
and overall patient survival. Clin Cancer Res. 14:6996–7003. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koya Y, Kajiyama H, Liu W, Shibata K,
Senga T and Kikkawa F: Murine experimental model of original tumor
development and peritoneal metastasis via orthotopic inoculation
with ovarian carcinoma cells. J Vis Exp. 9:543532016.
|
|
18
|
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: SPOCK1 as a potential
cancer prognostic marker promotes the proliferation and metastasis
of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol
Cancer. 14:122015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tian F, Xu F, Zhang ZY, Ge JP, Wei ZF, Xu
XF and Cheng W: Expression of CHD1L in bladder cancer and its
influence on prognosis and survival. Tumor Biol. 34:3687–3690.
2013. View Article : Google Scholar
|
|
20
|
Ji X, Li J, Zhu L, Cai J, Zhang J, Qu Y,
Zhang H, Liu B, Zhao R and Zhu Z: CHD1L promotes tumor progression
and predicts survival in colorectal carcinoma. J Surg Res.
185:84–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhong D, He G, Zhao S, Li J, Lang Y, Ye W,
Li Y, Jiang C and Li X: LRG1 modulates invasion and migration of
glioma cell lines through TGF-β signaling pathway. Acta Histochem.
117:551–558. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu X, He Y, Miao X, Wu Y, Han J, Wang Q,
Liu J, Zhong F, Ou Y, Wang Y and He S: Cell adhesion induces
overexpression of chromodomain helicase/ATPase DNA binding protein
1-like gene (CHD1L) and contributes to cell adhesion-mediated drug
resistance (CAM-DR) in multiple myeloma cells. Leuk Res. 47:54–62.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu
MZ and Xie D: Overexpression of CHD1L is positively associated with
metastasis of lung adenocarcinoma and predicts patients poor
survival. Oncotarget. 6:31181–31190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu C, Fu X, Zhong Z, Zhang J, Mou H, Wu
Q, Sheng T, Huang B and Zou Y: CHD1L expression increases tumor
progression and acts as a predictive biomarker for poor prognosis
in pancreatic cancer. Dig Dis Sci. 62:2376–2385. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He Q, Cai L, Shuai L, Li D, Wang C, Liu Y,
Li X, Li Z and Wang S: Ars2 is overexpressed in human
cholangiocarcinomas and its depletion increases PTEN and PDCD4 by
decreasing microRNA-21. Mol Carcinog. 52:286–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang XQ, Xu YF, Guo S, Liu Y, Ning SL, Lu
XF, Yang H and Chen YX: Clinical significance of nerve growth
factor and tropomyosin-receptor-kinase signaling pathway in
intrahepatic cholangiocarcinoma. World J Gastroenterol.
20:4076–4084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen G, Lin Y, Yang X, Zhang J, Xu Z and
Jia H: MicroRNA-26b inhibits epithelial-mesenchymal transition in
hepatocellular carcinoma by targeting USP9X. BMC Cancer.
14:3932014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Green DR and Chipuk JE: p53 and
metabolism: Inside the TIGAR. Cell. 126:30–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zolota V, Sirinian C, Melachrinou M,
Symeonidis A and Bonikos DS: Expression of the regulatory cell
cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone
marrow biopsies with acute myeloid leukemia. Correlation with
patients' survival. Pathol Res Pract. 203:199–207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen M, Huang JD, Hu L, Zheng BJ, Chen L,
Tsang SL and Guan XY: Transgenic CHD1L expression in mouse induces
spontaneous tumors. PLoS One. 4:e67272009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
López-Soto A, Gonzalez S, Smyth MJ and
Galluzzi L: Control of metastasis by NK cells. Cancer Cell.
32:135–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou W, Ye XL, Xu J, Cao MG, Fang ZY, Li
LY, Guan GH, Liu Q, Qian YH and Xie D: The lncRNA H19 mediates
breast cancer cell plasticity during EMT and MET plasticity by
differentially sponging miR-200b/c and let-7b. Sci Signal.
10:eaak95572017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen L, Chan TH, Yuan YF, Hu L, Huang J,
Ma S, Wang J, Dong SS, Tang KH, Xie D, et al: CHD1L promotes
hepatocellular carcinoma progression and metastasis in mice and is
associated with these processes in human patients. J Clin Invest.
120:1178–1191. 2010. View Article : Google Scholar : PubMed/NCBI
|
